IP Library › Granted Patent US 7,888,119
Granted Patent B2
US 7,888,119 · App. 11/582,057 · Granted Feb 15, 2011

Tissue substitutes comprising stem cells and reduced ceria

Assignee: University of Central Florida Research Foundation, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,888,119
App. No.
11/582,057
Granted
Feb 15, 2011
Kind
B2
Abstract

A biocompatible composite includes a solid biocompatible material and a plurality of living human progenitor or living stem cells attached thereto. The biocomposite provides a stable interface with endogenous tissue and the implanted composition resulting in accelerated repair to damaged bones and tissues.

Claims (19)

1. A biocomposite, comprising:

a biocompatible solid material, and

a plurality of living human progenitor or living stem cells attached to a surface of said biocompatible material;

wherein the biocompatible material comprises cerium nanoparticles on surfaces of said biocompatible material;

wherein the cerium nanoparticles comprise ceria nanoparticles having Ce 4+ molecules and reduced ceria nanoparticles having Ce 3+ molecules, the cerium nanoparticles having an average particle size of less than 20 nm; and

wherein the average particle size of less than 20 nm is effective to provide an increased amount of the reduced ceria nanoparticles on the surfaces of said biocompatible material relative to larger cerium nanoparticles.

2. The biocomposite of claim 1 , wherein said biocompatible material is a porous material.

3. The biocomposite of claim 1 , wherein said biocompatible material comprises ceria stabilized zirconia.

4. The biocomposite of claim 1 , wherein the surface of the biocompatible material comprises about 10% to about 90% Ce 3+ molecules versus Ce 4+ molecules.

5. The biocomposite of claim 1 , wherein the surface of the biocompatible material comprises at least 10% Ce 3+ molecules versus Ce 4+ molecules.

6. The biocomposite of claim 1 , wherein the surface of the biocompatible material comprises about 20% Ce 3+ molecules versus Ce 4+ molecules.

7. The biocomposite of claim 1 , wherein the surface of the biocompatible material comprises about 30% Ce 3+ molecules versus Ce 4+ molecules.

8. The biocomposite of claim 1 , wherein the surface of the biocompatible material comprises about 10% to about 99% Ce 4+ molecules versus Ce 3+ molecules.

9. The biocomposite of claim 1 , wherein the stem cells are derived from autologous bone marrow.

10. The biocomposite of claim 1 wherein the stem cells are selected from Lin − , Sca-1 + , or c-kit + .

11. The biocomposite of claim 1 , wherein said biocompatible material comprises a porous, near-net shape macroscopic article formed using a plasma spraying process.

12. The biocomposite of claim 1 , wherein said biocompatible material further comprises a coating of cell-adhesion molecules.

13. The biocomposite of claim 1 , wherein said plurality of living human progenitor or living stem cells have been contacted with a gene encoding a bone morphogenic protein.

14. The biocomposite of claim 1 , wherein the cerium nanoparticles are in a non-agglomerated state.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2009
From: SUGAYA, KIMINOBU; MERCHANT, STEPHANIE; SEAL, SUDIPTA; GEORGIEVA, PETYA; VROTSOS, MANNY
To: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 022308/0098 →
Continuity (2)
Provisional Application 60727075 · Oct 14, 2005
Related Publication 20070123996A1 · May 31, 2007